16 research outputs found

    The effects of platelet-rich plasma(PRP) in combination with anorganic bovine bone(Bio-Oss๏ผŸ) on the early wound healing of rabbit cranial defects

    No full text
    ํ˜ˆ์†ŒํŒ ๋†์ถ• ํ˜ˆ์žฅ์€ ๊ตฌ๊ฐ•๊ณผ ์•ˆ๋ฉด๋ถ€ ์žฌ๊ฑด์ˆ˜์ˆ ์— ์ƒˆ๋กœ์ด ์‚ฌ์šฉ๋˜๋Š” ์œ ์šฉํ•œ ์ฒจ๊ฐ€๋ฌผ์ด๋‹ค. ํ˜ˆ์†ŒํŒ์€ ์ƒ์ฒ˜ ์น˜์œ ๊ณผ์ •์—์„œ ๋งค์šฐ ์ค‘์š”ํ•˜๋ฉฐ, ํ˜ˆ์†ŒํŒ์€ ์ƒ์ฒ˜๋ถ€์œ„์— ๋น ๋ฅด๊ฒŒ ๋„๋‹ฌํ•˜์—ฌ ์‘๊ณ ๋ฅผ ํ˜•์„ฑํ•œ๋‹ค. ๊ทธ๋ฆฌ๊ณ  ๋‹ค์–‘ํ•œ ์„ฑ์žฅ์ธ์ž๋ฅผ ๋ถ„๋น„ํ•œ๋‹ค. ์ด๋Ÿฌํ•œ ์„ฑ์žฅ์ธ์ž๋Š” ๊ณจ์˜ ํ˜•์„ฑ๊ณผ ํ˜ˆ๊ด€์˜ ์ฆ๊ฐ€, ๊ณจ ์ด์‹์žฌ์˜ ์น˜์œ ์— ๊ด€์—ฌํ•˜๋Š” ๊ฒƒ์œผ๋กœ ์ƒ๊ฐ๋œ๋‹ค. ๋ณธ ์—ฐ๊ตฌ์˜ ๋ชฉ์ ์€ ์‹คํ—˜ ๋™๋ฌผ์„ ํ†ตํ•˜์—ฌ ํ˜ˆ์†ŒํŒ ๋†์ถ• ํ˜ˆ์žฅ์— ํ•จ์œ ๋œ ํ˜ˆ์†ŒํŒ์˜ ์ •๋Ÿ‰ํ™”๋ฅผ ํ†ตํ•œ ์„ฑ์žฅ์ธ์ž ํ•จ์œ ๋Ÿ‰์„ ์ถ”์ •ํ•˜๊ณ , ๋ฐฉ์‚ฌ์„ ํ•™์ , ์กฐ์งํ•™์  ํ‰๊ฐ€๋ฅผ ํ†ตํ•ด ํ˜ˆ์†ŒํŒ ๋†์ถ• ํ˜ˆ์žฅ์ด ์ดˆ๊ธฐ์˜ ๊ณจํ˜•์„ฑ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์— ๋Œ€ํ•œ ํ‰๊ฐ€๋ฅผ ํ•˜๋Š”๋ฐ ์žˆ๋‹ค. 15๋งˆ๋ฆฌ์˜ ๊ฐ€ํ†  ๋‘๊ฐœ๊ณจ์— 6mm trephine bur(์™ธ๊ฒฝ 8mm)๋ฅผ ์ด์šฉํ•˜์—ฌ ๊ฒฝ๋‡Œ๋ง‰์˜ ์†์ƒ์„ ์ฃผ์ง€ ์•Š๋„๋ก ํ•˜๋ฉด์„œ 4๊ฐœ์˜ ๊ฒฐ์†๋ถ€๋ฅผ ํ˜•์„ฑํ•˜์˜€๋‹ค. ๊ฐ๊ฐ์˜ ๋‘๊ฐœ๊ณจ ๊ฒฐ์†๋ถ€๋Š” ๋งŒ ์ด์‹ํ•œ ๊ตฐ, PRP๋งŒ ์ด์‹ํ•œ ๊ตฐ, PRP์™€ ๋ฅผ ํ˜ผํ•ฉํ•˜์—ฌ ์ด์‹ํ•œ๊ตฐ, ๊ทธ๋ฆฌ๊ณ  ์•„๋ฌด๊ฒƒ๋„ ์ด์‹ํ•˜์ง€ ์•Š์€ ๊ตฐ์„ ๋Œ€์กฐ๊ตฐ์œผ๋กœ ์„ค์ •ํ•˜์˜€๋‹ค. ๊ฐ๊ฐ์˜ ์žฌ๋ฃŒ๋ฅผ ์ด์‹ํ•œ ํ›„ ๋น„ํก์ˆ˜์„ฑ ์ฐจํ๋ง‰()์„ ์œ„์น˜์‹œํ‚ค๊ณ  ํก์ˆ˜์„ฑ ๋ด‰ํ•ฉ์‚ฌ๋กœ ์ผ์ฐจ๋ด‰ํ•ฉ์„ ์‹œํ–‰ํ•˜์˜€๋‹ค. ๊ฐ ๊ตฐ ๋‹น ์ˆ  ํ›„ 1, 2, 4์ฃผ์˜ ์น˜์œ ๊ธฐ๊ฐ„์„ ์„ค์ •ํ•˜์˜€๋‹ค. ๋™๋ฌผ์„ ํฌ์ƒ์‹œํ‚ค๊ณ  ๋‘๊ฐœ๊ณจ์„ ์ ˆ์ œํ•˜์˜€๋‹ค. ๋จผ์ € ๋ฐฉ์‚ฌ์„ ํ•™์ ์ธ ๊ณจ ๋ฐ€๋„ ์ธก์ •์„ ์‹œํ–‰ํ•˜๊ณ , ์กฐ์งํ•™์  ํ‰๊ฐ€๋ฅผ ์œ„ํ•ด ํ†ต๋ฒ•์— ๋”ฐ๋ผ ์กฐ์ง ํ‘œ๋ณธ์„ ์ œ์ž‘ํ•œ ํ›„ ๊ด‘ํ•™ํ˜„๋ฏธ๊ฒฝ์œผ๋กœ ๊ด€์ฐฐํ•˜์˜€๋‹ค. ๋˜ํ•œ ๊ฐ€ํ†  ๊ท€ ๋ณ€์—ฐ์ •๋งฅ์—์„œ ์ฑ„์ทจํ•œ 10 ml์˜ ํ˜ˆ์•ก์„ ์›์‹ฌ๋ถ„๋ฆฌํ•˜์—ฌ ํ˜ˆ์†ŒํŒ ํ•จ์œ ๋Ÿ‰์„ ํ‰๊ฐ€ํ•˜์—ฌ ๋‹ค์Œ๊ณผ ๊ฐ™์€ ๊ฒฐ๊ณผ๋ฅผ ์–ป์—ˆ๋‹ค. 1. ํ˜ˆ์†ŒํŒ ๋†์ถ• ํ˜ˆ์žฅ์€ ์ผ๋ฐ˜ ํ˜ˆ์•ก์— ๋น„ํ•ด ์•ฝ 4.02๋ฐฐ ๋งŽ์€ ์ˆ˜์˜ ํ˜ˆ์†ŒํŒ์ด ํ•จ์œ ๋˜์–ด ์žˆ์—ˆ๋‹ค. 2. ๋ฐฉ์‚ฌ์„ ์ ์ธ ํ‰๊ฐ€์—์„œ 1, 2, 4์ฃผ ์‚ฌ์ด์— ๋Œ€์กฐ๊ตฐ๊ณผ ๋น„๊ตํ•˜์—ฌ ์— PRP๋ฅผ ์ด์‹ํ•œ ๊ตฐ์—์„œ ๊ณจ์˜ ๋ฐ€๋„๋Š” ํฐ ์ฐจ์ด๋ฅผ ๋ณด์ด๊ณ  ์žˆ๋‹ค(p0.05), ๋งŒ ์ด์‹ํ•œ ๊ตฐ๊ณผ ์— PRP๋ฅผ ์ด์‹ํ•œ ๊ตฐ์˜ ์ฐจ์ด ๋˜ํ•œ ๋ฐœ๊ฒฌํ•  ์ˆ˜ ์—†์—ˆ๋‹ค(p>0.05). 3. ์กฐ์งํ•™์  ํ‰๊ฐ€์—์„œ ๋ชจ๋“  ์ด์‹์žฌ๋Š” ์‹œ๊ฐ„์ด ๊ฒฝ๊ณผํ• ์ˆ˜๋ก ๊ณจ ํ˜•์„ฑ์ด ์ฆ๊ฐ€ํ•จ์„ ์•Œ ์ˆ˜ ์žˆ์—ˆ๋‹ค. ๋Œ€์กฐ๊ตฐ์— ๋น„ํ•ด PRP๋งŒ ์ด์‹ํ•œ ๊ตฐ์—์„œ ๋” ๋‘๊บผ์šด ์„ฌ์œ ์„ฑ ๊ฒฐํ•ฉ์„ ๋ณด์ด๊ณ  ์žˆ๋‹ค. ๋Œ€์กฐ๊ตฐ๊ณผ PRP๋งŒ ์ด์‹ํ•œ ๊ตฐ๊ณผ ๋น„๊ตํ•ด ์™€ ์— PRP๋ฅผ ํ˜ผํ•ฉ ์ด์‹ํ•œ ๊ตฐ์—์„œ ๊ณจ์˜ ํ˜•์„ฑ์ด ๋” ์ง„ํ–‰๋จ์„ ์•Œ ์ˆ˜ ์žˆ์—ˆ๋‹ค. ์— PRP๋ฅผ ํ˜ผํ•ฉ ์ด์‹ํ•œ ๊ตฐ์ด ๋งŒ ์ด์‹ํ•œ ๊ตฐ์—์„œ๋ณด๋‹ค ๋” ๋งŽ์€ ์‹ ์ƒ๊ณจ ํ˜•์„ฑ์„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค. ์ด์ƒ์˜ ๊ฒฐ๊ณผ์—์„œ ๊ฐ€ํ† ์˜ ๋‘๊ฐœ๊ณจ ๊ฒฐ์†๋ถ€์— ์— PRP๋ฅผ ํ˜ผํ•ฉ ์ด์‹ํ•˜์˜€์„ ๊ฒฝ์šฐ ๊ฒฐ์†๋ถ€์˜ ์ดˆ๊ธฐ ๊ณจ ํ˜•์„ฑ์„ ์ด‰์ง„ ํ•  ์ˆ˜ ์žˆ์Œ์„ ์‹œ์‚ฌํ•˜์˜€๋‹ค.This study was supported by a grant of the Korea Health 21 R& D Projectm ministry of Health & Welfare, Republic of Kore

    ํ˜ˆ์†ŒํŒ ๋†์ถ• ํ˜ˆ์žฅ๊ณผ ํ˜ผํ•ฉ๋œ ์ด์ข…๊ณจ ์ด์‹์žฌ(Bio-Ossยฎ)๊ฐ€ ๊ฐ€ํ†  ๋‘๊ฐœ๊ณจ ๊ฒฐ์†๋ถ€ ์ดˆ๊ธฐ ์น˜์œ ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ

    No full text
    ํ˜ˆ์†ŒํŒ ๋†์ถ• ํ˜ˆ์žฅ์€ ๊ตฌ๊ฐ•๊ณผ ์•ˆ๋ฉด๋ถ€ ์žฌ๊ฑด์ˆ˜์ˆ ์— ์ƒˆ๋กœ์ด ์‚ฌ์šฉ๋˜๋Š” ์œ ์šฉํ•œ ์ฒจ๊ฐ€๋ฌผ์ด๋‹ค. ํ˜ˆ์†ŒํŒ์€ ์ƒ์ฒ˜ ์น˜์œ ๊ณผ์ •์—์„œ ๋งค์šฐ ์ค‘์š”ํ•˜๋ฉฐ, ํ˜ˆ์†ŒํŒ์€ ์ƒ์ฒ˜๋ถ€์œ„์— ๋น ๋ฅด๊ฒŒ ๋„๋‹ฌํ•˜์—ฌ ์‘๊ณ ๋ฅผ ํ˜•์„ฑํ•œ๋‹ค. ๊ทธ๋ฆฌ๊ณ  ๋‹ค์–‘ํ•œ ์„ฑ์žฅ์ธ์ž๋ฅผ ๋ถ„๋น„ํ•œ๋‹ค. ์ด๋Ÿฌํ•œ ์„ฑ์žฅ์ธ์ž๋Š” ๊ณจ์˜ ํ˜•์„ฑ๊ณผ ํ˜ˆ๊ด€์˜ ์ฆ๊ฐ€, ๊ณจ ์ด์‹์žฌ์˜ ์น˜์œ ์— ๊ด€์—ฌํ•˜๋Š” ๊ฒƒ์œผ๋กœ ์ƒ๊ฐ๋œ๋‹ค. ๋ณธ ์—ฐ๊ตฌ์˜ ๋ชฉ์ ์€ ์‹คํ—˜ ๋™๋ฌผ์„ ํ†ตํ•˜์—ฌ ํ˜ˆ์†ŒํŒ ๋†์ถ• ํ˜ˆ์žฅ์— ํ•จ์œ ๋œ ํ˜ˆ์†ŒํŒ์˜ ์ •๋Ÿ‰ํ™”๋ฅผ ํ†ตํ•œ ์„ฑ์žฅ์ธ์ž ํ•จ์œ ๋Ÿ‰์„ ์ถ”์ •ํ•˜๊ณ , ๋ฐฉ์‚ฌ์„ ํ•™์ , ์กฐ์งํ•™์  ํ‰๊ฐ€๋ฅผ ํ†ตํ•ด ํ˜ˆ์†ŒํŒ ๋†์ถ• ํ˜ˆ์žฅ์ด ์ดˆ๊ธฐ์˜ ๊ณจํ˜•์„ฑ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์— ๋Œ€ํ•œ ํ‰๊ฐ€๋ฅผ ํ•˜๋Š”๋ฐ ์žˆ๋‹ค. 15๋งˆ๋ฆฌ์˜ ๊ฐ€ํ†  ๋‘๊ฐœ๊ณจ์— 6mm trephine bur(์™ธ๊ฒฝ 8mm)๋ฅผ ์ด์šฉํ•˜์—ฌ ๊ฒฝ๋‡Œ๋ง‰์˜ ์†์ƒ์„ ์ฃผ์ง€ ์•Š๋„๋ก ํ•˜๋ฉด์„œ 4๊ฐœ์˜ ๊ฒฐ์†๋ถ€๋ฅผ ํ˜•์„ฑํ•˜์˜€๋‹ค. ๊ฐ๊ฐ์˜ ๋‘๊ฐœ๊ณจ ๊ฒฐ์†๋ถ€๋Š” Bio-Ossยฎ๋งŒ ์ด์‹ํ•œ ๊ตฐ, PRP๋งŒ ์ด์‹ํ•œ ๊ตฐ, PRP์™€ Bio-Ossยฎ๋ฅผ ํ˜ผํ•ฉํ•˜์—ฌ ์ด์‹ํ•œ๊ตฐ, ๊ทธ๋ฆฌ๊ณ  ์•„๋ฌด๊ฒƒ๋„ ์ด์‹ํ•˜์ง€ ์•Š์€ ๊ตฐ์„ ๋Œ€์กฐ๊ตฐ์œผ๋กœ ์„ค์ •ํ•˜์˜€๋‹ค. ๊ฐ๊ฐ์˜ ์žฌ๋ฃŒ๋ฅผ ์ด์‹ํ•œ ํ›„ ๋น„ํก์ˆ˜์„ฑ ์ฐจํ๋ง‰(Tefgenยฎ)์„ ์œ„์น˜์‹œํ‚ค๊ณ  ํก์ˆ˜์„ฑ ๋ด‰ํ•ฉ์‚ฌ๋กœ ์ผ์ฐจ๋ด‰ํ•ฉ์„ ์‹œํ–‰ํ•˜์˜€๋‹ค. ๊ฐ ๊ตฐ ๋‹น ์ˆ  ํ›„ 1, 2, 4์ฃผ์˜ ์น˜์œ ๊ธฐ๊ฐ„์„ ์„ค์ •ํ•˜์˜€๋‹ค. ๋™๋ฌผ์„ ํฌ์ƒ์‹œํ‚ค๊ณ  ๋‘๊ฐœ๊ณจ์„ ์ ˆ์ œํ•˜์˜€๋‹ค. ๋จผ์ € ๋ฐฉ์‚ฌ์„ ํ•™์ ์ธ ๊ณจ ๋ฐ€๋„ ์ธก์ •์„ ์‹œํ–‰ํ•˜๊ณ , ์กฐ์งํ•™์  ํ‰๊ฐ€๋ฅผ ์œ„ํ•ด ํ†ต๋ฒ•์— ๋”ฐ๋ผ ์กฐ์ง ํ‘œ๋ณธ์„ ์ œ์ž‘ํ•œ ํ›„ ๊ด‘ํ•™ํ˜„๋ฏธ๊ฒฝ์œผ๋กœ ๊ด€์ฐฐํ•˜์˜€๋‹ค. ๋˜ํ•œ ๊ฐ€ํ†  ๊ท€ ๋ณ€์—ฐ์ •๋งฅ์—์„œ ์ฑ„์ทจํ•œ 10 ml์˜ ํ˜ˆ์•ก์„ ์›์‹ฌ๋ถ„๋ฆฌํ•˜์—ฌ ํ˜ˆ์†ŒํŒ ํ•จ์œ ๋Ÿ‰์„ ํ‰๊ฐ€ํ•˜์—ฌ ๋‹ค์Œ๊ณผ ๊ฐ™์€ ๊ฒฐ๊ณผ๋ฅผ ์–ป์—ˆ๋‹ค. 1. ํ˜ˆ์†ŒํŒ ๋†์ถ• ํ˜ˆ์žฅ์€ ์ผ๋ฐ˜ ํ˜ˆ์•ก์— ๋น„ํ•ด ์•ฝ 4.02๋ฐฐ ๋งŽ์€ ์ˆ˜์˜ ํ˜ˆ์†ŒํŒ์ด ํ•จ์œ ๋˜์–ด ์žˆ์—ˆ๋‹ค. 2. ๋ฐฉ์‚ฌ์„ ์ ์ธ ํ‰๊ฐ€์—์„œ 1, 2, 4์ฃผ ์‚ฌ์ด์— ๋Œ€์กฐ๊ตฐ๊ณผ ๋น„๊ตํ•˜์—ฌ Bio-Ossยฎ์— PRP๋ฅผ ์ด์‹ํ•œ ๊ตฐ์—์„œ ๊ณจ์˜ ๋ฐ€๋„๋Š” ํฐ ์ฐจ์ด๋ฅผ ๋ณด์ด๊ณ  ์žˆ๋‹ค(p0.05), Bio-Ossยฎ๋งŒ ์ด์‹ํ•œ ๊ตฐ๊ณผ Bio-Ossยฎ์— PRP๋ฅผ ์ด์‹ํ•œ ๊ตฐ์˜ ์ฐจ์ด ๋˜ํ•œ ๋ฐœ๊ฒฌํ•  ์ˆ˜ ์—†์—ˆ๋‹ค(p>0.05). 3. ์กฐ์งํ•™์  ํ‰๊ฐ€์—์„œ ๋ชจ๋“  ์ด์‹์žฌ๋Š” ์‹œ๊ฐ„์ด ๊ฒฝ๊ณผํ• ์ˆ˜๋ก ๊ณจ ํ˜•์„ฑ์ด ์ฆ๊ฐ€ํ•จ์„ ์•Œ ์ˆ˜ ์žˆ์—ˆ๋‹ค. ๋Œ€์กฐ๊ตฐ์— ๋น„ํ•ด PRP๋งŒ ์ด์‹ํ•œ ๊ตฐ์—์„œ ๋” ๋‘๊บผ์šด ์„ฌ์œ ์„ฑ ๊ฒฐํ•ฉ์„ ๋ณด์ด๊ณ  ์žˆ๋‹ค. ๋Œ€์กฐ๊ตฐ๊ณผ PRP๋งŒ ์ด์‹ํ•œ ๊ตฐ๊ณผ ๋น„๊ตํ•ด Bio-Ossยฎ์™€ Bio-Ossยฎ์— PRP๋ฅผ ํ˜ผํ•ฉ ์ด์‹ํ•œ ๊ตฐ์—์„œ ๊ณจ์˜ ํ˜•์„ฑ์ด ๋” ์ง„ํ–‰๋จ์„ ์•Œ ์ˆ˜ ์žˆ์—ˆ๋‹ค. Bio-Ossยฎ์— PRP๋ฅผ ํ˜ผํ•ฉ ์ด์‹ํ•œ ๊ตฐ์ด Bio-Ossยฎ๋งŒ ์ด์‹ํ•œ ๊ตฐ์—์„œ๋ณด๋‹ค ๋” ๋งŽ์€ ์‹ ์ƒ๊ณจ ํ˜•์„ฑ์„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค. ์ด์ƒ์˜ ๊ฒฐ๊ณผ์—์„œ ๊ฐ€ํ† ์˜ ๋‘๊ฐœ๊ณจ ๊ฒฐ์†๋ถ€์— Bio-Ossยฎ์— PRP๋ฅผ ํ˜ผํ•ฉ ์ด์‹ํ•˜์˜€์„ ๊ฒฝ์šฐ ๊ฒฐ์†๋ถ€์˜ ์ดˆ๊ธฐ ๊ณจ ํ˜•์„ฑ์„ ์ด‰์ง„ ํ•  ์ˆ˜ ์žˆ์Œ์„ ์‹œ์‚ฌํ•˜์˜€๋‹ค.This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea(03-PJ1-PG1-CH08-0001)

    Efficacy and safety of standard dose triple combination of telmisartan 80ย mg/amlodipine 5ย mg/chlorthalidone 25ย mg in primary hypertension: A randomized, doubleโ€blind, activeโ€controlled, multicenter phase 3 trial

    No full text
    Abstract The authors evaluated the efficacy, safety, and characteristics of patients who respond well to standard dose triple combination therapy including chlorthalidone 25ย mg with telmisartan 80ย mg plus amlodipine 5ย mg in hypertensive patients. This is a multicenter, doubleโ€blind, activeโ€controlled, phase 3, randomized trial. Patients are randomized to triple combination (telmisartan 40ย mg/amlodipine 5ย mg/chlorthalidone 12.5ย mg, TEL/AML/CHTD group) or dual combination (telmisartan 40ย mg/amlodipine 5ย mg, TEL/AML group) treatment and then dose up titration to TEL 80/AML5/CHTD25mg and TEL80/AML5, respectively. The primary endpoint is the change of mean sitting systolic blood pressure (MSSBP) at week 8. A Target BP achievement rate, a response rate, and the safety endpoints are also evaluated. Total 374 patients (mean ageย =ย 60.9ย ยฑย 10.7ย years, maleย =ย 78.3%) were randomized to the study. The baseline MSSBPs/diastolic BPs were 149.9ย ยฑย 12.2/88.5ย ยฑย 10.4ย mm Hg. After 8ย weeks treatment, the change of MSSBPs at week 8 are โˆ’19.1ย ยฑย 14.9ย mm Hg (TEL/AML/CHTD) and โˆ’11.4ย ยฑย 14.7ย mm Hg (TEL/AML) (pย <ย .0001). The achievement rates of target BP (53.8% vs. 37.8%, pย =ย .0017) and responder rate (54.8% vs. 35.6%, pย =ย .0001) at week 8 were significantly higher in TEL/AML/CHTD. There are no serious adverse event and no one discontinued medication due to adverse event. Among the TEL 80/AML5/CHTD25mg treatment group, patients of female or ageย โ‰ฅย 65ย years old showed higher rate of target BP achievement than relatively young male. (61.4 vs. 46.8%, pย =ย .042) Our study showed standard dose triple combination of telmisartan 80ย mg/amlodipine 5ย mg/chlorthalidone 25ย mg is efficacious and safe in treatment of primary hypertension. Target BP achievement with triple therapy would be facilitated in female or old age

    Off-Hour Effect on 3-Month Functional Outcome after Acute Ischemic Stroke: A Prospective Multicenter Registry

    No full text
    <div><p>Background and Purpose</p><p>The time of hospital arrival may have an effect on prognosis of various vascular diseases. We examined whether off-hour admission would affect the 3-month functional outcome in acute ischemic stroke patients admitted to tertiary hospitals.</p><p>Methods</p><p>We analyzed the โ€˜off-hour effectโ€™ in consecutive patients with acute ischemic stroke using multi-center prospective stroke registry. Work-hour admission was defined as when the patient arrived at the emergency department between 8 AM and 6 PM from Monday to Friday and between 8 AM and 1 PM on Saturday. Off-hour admission was defined as the rest of the work-hours and statutory holidays. Multivariable logistic regression was used to analyze the association between off-hour admission and 3-month unfavorable functional outcome defined as modified Rankin Scale (mRS) 3โ€“6. Multivariable model included age, sex, risk factors, prehospital delay time, intravenous thrombolysis, stroke subtypes and severity as covariates.</p><p>Results</p><p>A total of 7075 patients with acute ischemic stroke were included in this analysis: mean age, 67.5 (ยฑ13.0) years; male, 58.6%. In multivariable analysis, off-hour admission was not associated with unfavorable functional outcome (OR, 0.89; 95% CI, 0.72โ€“1.09) and mortality (OR, 1.09; 95% CI, 0.77โ€“1.54) at 3 months. Moreover, off-hour admission did not affect a statistically significant shift of 3-month mRS distributions (OR, 0.90; 95% CI, 0.78โ€“1.05).</p><p>Conclusions</p><p>โ€˜Off-hourโ€™ admission is not associated with an unfavorable 3-month functional outcome in acute ischemic stroke patients admitted to tertiary hospitals in Korea. This finding indicates that the off-hour effects could be overcome with well-organized stroke management strategies.</p></div
    corecore